Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform

Rhea-AI Summary

Abbott (NYSE: ABT) received FDA clearance and a CE Mark for Ultreon 3.0, its next-generation AI-powered coronary imaging platform, on April 28, 2026. Ultreon 3.0 combines high-resolution OCT imaging, a one-second OCT pullback, and AI-automated insights to support planning, stent sizing, and post-procedure assessment for complex PCI.

The platform aims to speed workflows, reduce contrast use (relevant for ~25% of CAD patients with kidney disease), and provide real-time guidance to clinicians treating complex coronary artery disease.

AI-generated analysis. Not financial advice.

Positive

• Regulatory approvals: FDA clearance and CE Mark for Ultreon 3.0
• Technical upgrade: one-second OCT pullback enabling high-resolution intravascular imaging
• AI-guided care: automated stent sizing and placement guidance to support procedural planning and post-procedure assessment

Negative

• None.

News Market Reaction – ABT

+1.14%

1 alert

+1.14% News Effect

On the day this news was published, ABT gained 1.14%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

OCT pullback time: 1 second Kidney disease share: 25% PCI volume US: 600,000 procedures +1 more

4 metrics

OCT pullback time 1 second Ultreon 3.0 OCT pullback duration for coronary imaging

Kidney disease share 25% Approximate share of coronary artery disease patients with kidney disease

PCI volume US 600,000 procedures Estimated annual PCI procedures in the U.S.

PCI volume Europe 885,000 procedures Estimated annual PCI procedures in Europe

Market Reality Check

Price: $85.42 Vol: Price at 92.8 with volume...

normal vol

$85.42 Last Close

Volume Price at 92.8 with volume 15,052,383 vs 20-day average 12,210,301 (relative volume 1.23). normal

Technical Shares trade below the 200-day MA of 121.36 and sit close to the 52-week low of 90.72, well under the 52-week high of 139.06.

Peers on Argus

ABT shows a positive 1.83% move while key medical device peers are mixed: BSX (-...

ABT shows a positive 1.83% move while key medical device peers are mixed: BSX (-2.06%), MDT (-0.24%), SYK (+0.74%), EW (+0.07%), SNN (+1.17%). This pattern points to a stock-specific reaction rather than a broad sector rotation.

Common Catalyst Several device peers also reported news (e.g., MDT CE Mark system, EW conference appearance), suggesting a flow of product and event updates across the medical device space, but without a unified price direction.

Historical Context

5 past events · Latest: Apr 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 17	Cancer test data	Positive	+1.4%	AACR 2026 data on Cancerguard multi-biomarker early cancer detection test.
Apr 16	Earnings and M&A	Neutral	-6.0%	Q1 2026 results, updated guidance and completion of Exact Sciences acquisition.
Apr 09	Health survey release	Neutral	-0.8%	Nationwide survey on chronic disease perceptions and health confidence in U.S. adults.
Mar 30	Oncology integration	Positive	-2.0%	Integration of Precision Oncology portfolio into Flatiron’s OncoEMR platform.
Mar 26	Earnings call notice	Neutral	-0.3%	Announcement of date and time for first‑quarter 2026 earnings call and webcast.

Pattern Detected

Recent news, including positive clinical and strategic updates, often coincided with flat-to-negative price reactions, showing a tendency toward muted or contrarian trading around catalysts.

Recent Company History

Over the last month, Abbott has reported multiple developments: Q1 2026 results with $11,164 million sales and updated guidance tied to the Exact Sciences acquisition on Apr 16, 2026, oncology integration with Flatiron’s OncoEMR on Mar 30, and new Cancerguard data shared at AACR on Apr 17. Despite these product and data advances, several events saw negative or modest price moves, so today’s AI-powered Ultreon 3.0 clearance and CE Mark arrive against a backdrop of cautious trading responses.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-02-23

Abbott has an effective Form S-3ASR shelf prospectus dated February 23, 2026, allowing offerings of debt securities, common and preferred shares, depositary shares, warrants, purchase contracts and units from time to time. The shelf has already been used via 424B3 and 424B5 filings in February 2026, indicating an established framework for potential future capital or financing transactions.

Market Pulse Summary

This announcement highlights dual FDA clearance and CE Mark for Abbott’s Ultreon 3.0 AI-powered OCT ...

Analysis

This announcement highlights dual FDA clearance and CE Mark for Abbott’s Ultreon 3.0 AI-powered OCT platform, aimed at improving complex PCI planning and stent placement. In recent months, Abbott has also advanced oncology diagnostics, completed the Exact Sciences deal, and integrated tests into major oncology workflows. Investors may watch adoption trends in PCI volumes, additional clinical data, and how this technology complements the broader Medical Devices growth narrative.

Key Terms

optical coherence tomography (OCT), percutaneous coronary intervention (PCI), intravascular ultrasound (IVUS), CE Mark, +2 more

6 terms

optical coherence tomography (OCT) medical

"Ultreon 3.0 is an artificial intelligence (AI) powered imaging platform that uses optical coherence tomography (OCT)"

Optical coherence tomography (OCT) is a noninvasive imaging technique that uses light to create detailed, cross‑sectional pictures of internal tissues, most commonly the eye and blood vessels. Investors care because OCT is a diagnostic and procedural guidance tool that drives sales of specialized scanners, software and disposables; think of it as a high‑precision camera that lets doctors see tiny layers and make faster, more accurate treatment decisions.

percutaneous coronary intervention (PCI) medical

"procedures to open blocked heart arteries known as percutaneous coronary intervention (PCI)"

A percutaneous coronary intervention (PCI) is a minimally invasive procedure that uses a thin tube threaded to the heart to open narrowed or blocked coronary arteries, often by inflating a small balloon and leaving a metal mesh tube (stent) in place — think of clearing a clogged pipe and propping it open. Investors care because PCI drives demand for medical devices, influences hospital procedure volumes and reimbursement, and affects long-term patient outcomes and healthcare costs, all of which can materially impact company revenues and sector earnings.

intravascular ultrasound (IVUS) medical

"offering higher resolution readings than intravascular ultrasound (IVUS) and with low or zero contrast"

Intravascular ultrasound (IVUS) is a medical imaging technique that uses a tiny ultrasound probe threaded inside a blood vessel to create detailed cross‑sectional pictures of the vessel wall, plaque and stents. Think of it as a small camera that shows the inside of a pipe to reveal blockages and how well repairs fit. Investors care because IVUS can influence how often certain devices and procedures are used, affect clinical outcomes, reimbursement and regulatory approvals, and therefore impact revenue and adoption for companies in cardiovascular care.

CE Mark regulatory

"announced it received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon 3.0"

A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.

FDA clearance regulatory

"announced it received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon 3.0"

FDA clearance is the U.S. Food and Drug Administration’s official permission to market certain medical devices or diagnostic tests after reviewing evidence that they are as safe and effective as similar products already on the market. For investors, it’s like a product passing a required safety inspection — it reduces regulatory uncertainty, speeds commercial rollout, and can directly affect sales prospects, valuation, and partnership opportunities.

coronary artery disease medical

"people with coronary artery disease.i The AI and software capabilities of Ultreon 3.0 include"

Coronary artery disease is a condition in which the blood vessels that supply the heart become narrowed or blocked by fatty buildup, reducing oxygen-rich blood flow and making the heart work harder. For investors, it matters because the condition drives demand for medications, medical devices, diagnostics and procedures, can affect healthcare spending and payer policies, and influences the financial prospects of companies involved in cardiovascular care—similar to how a clogged pipe changes maintenance and replacement needs.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Ultreon 3.0 is the first advanced optical coherence tomography (OCT) system in the U.S. and Europe that integrates high resolution coronary plaque images and AI-automated insights through the artery
• The integrated imaging platform is designed to enable fast, intuitive decision making for physicians while treating complex coronary disease to open clogged arteries
• The AI enabled software helps physicians size and position the stent more accurately, which can lead to better results for patients

ABBOTT PARK, Ill., April 28, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 Software. This marks a major step forward as it brings coronary imaging and AI-automated insights together in one system to support better patient outcomes and help reduce risks.

Ultreon 3.0 is an artificial intelligence (AI) powered imaging platform that uses optical coherence tomography (OCT) to give doctors real-time planning guidance while they perform minimally invasive procedures to open blocked heart arteries known as percutaneous coronary intervention (PCI). This technology allows physicians to use OCT images to see the detailed structure of the blockage and incorporates AI to assess the type of plaque causing the blockage, helping the doctor choose the best location and size of the stent to improve blood flow. The platform offers a fully integrated workflow to support faster, more precise procedures.

"Ultreon 3.0 represents a pivotal step forward in how we treat and ultimately care for our patients. This next-generation platform, combining imaging and AI, doesn't just improve upon existing technology — it leapfrogs it," said Evan Shlofmitz, D.O., interventional cardiologist, director of interventional cardiology, St. Francis Hospital and Health Center in Roslyn, NY. "By delivering greater clarity, speed, and clinical insight, Ultreon 3.0 accelerates the path to more confident clinician decision making and transformative patient care."

"Abbott's Ultreon 3.0 offers a single, AI-driven platform that quickly and easily captures the images physicians need to fully understand the size and angle of the blockage, and create an actionable plan to help the patient," said David M. Leistner, interventional cardiologist, Clinic for Cardiology and Angiology, Charité Campus Benjamin-Franklin (CBF) in Berlin, Germany. "Every second and every decision matters when treating patients who have blockages in their coronary arteries, and Ultreon 3.0 enables faster, more informed clinical choices that can have a real impact on patients."

The next-generation software features a one-second OCT pullback, which is a high-speed infrared light-based imaging technique that quickly captures detailed cross-sectional views of the coronary artery, offering higher resolution readings than intravascular ultrasound (IVUS) and with low or zero contrast. Minimizing the amount of contrast may be helpful in some patients with kidney disease, who represent approximately 25% of people with coronary artery disease.ⁱ The AI and software capabilities of Ultreon 3.0 include the following additional benefits:

• A clear understanding of the size, shape, and location of a coronary blockage, enabling optimal stent placement to maximize blood flow and guide treatment planning.
• A post-procedure assessment to ensure the stent improved blood flow in the artery.
• A streamlined setup and enhanced AI-automated insights that simplify physicians' workflow.
• Easily acquired images from inside blood vessels and ability to efficiently plan procedures, specifically tailored for patients with complex coronary disease.

"Complemented by our leading coronary portfolio, Ultreon 3.0 makes OCT imaging more intuitive and powerful for physicians, reimagining imaging into a tool for precision-guided intervention before and after procedures," said Ethan Korngold, M.D., chief medical officer at Abbott's vascular business. "Advancements like Ultreon 3.0 showcase Abbott's leadership in AI-powered imaging and as a trusted partner in delivering smarter, more personalized coronary care."

Ultreon 3.0: Advancing Complex PCI:

Complex PCI is a specialized procedure used to treat severe coronary artery disease. PCI involves treating challenging lesions—or plaques—that have built up in a patient's coronary arteries. Some patients will require multiple stents to address the lesions. More than 600,000 people in the U.S. and more than 885,000 in Europe undergo PCI each year.^ii,iii

Ultreon 3.0 is an AI solution that meets real-world needs, advances clinical precision, and supports more consistent care delivery. Built on the success of Ultreon 2.0, this platform introduces enhanced AI capabilities to provide a simple, fast, and precise solution for complex coronary PCIs.

For important safety information on Ultreon 3.0 Software, visit: https://www.cardiovascular.abbott/us/en/hcp/products/percutaneous-coronary-intervention/intravascular-imaging/ultreon-software/important-safety-information.html 

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

ⁱ Mehdi, A., Taliercio, J. J., & Nakhoul, G. (2020, November 1). Contrast media in patients with kidney disease: An update. Cleveland Clinic Journal of Medicine. https://www.ccjm.org/content/87/11/683#:~:text=Nevertheless%2C%20CI%2DAKI%20remains%20real,24%25%20of%20patients%2C%20respectively.
ⁱⁱ Masoudi FA, Ponirakis A, de Lemos JA, Jollis JG, Kremers M, Messenger JC, et al. Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. J Am Coll Cardiol. 2017;69(11):1427–50.
ⁱⁱⁱ Cook S, Walker A, Hügli O, Togni M, Meier B. Percutaneous coronary interventions in Europe: prevalence, numerical estimates, and projections based on data up to 2004. Clin Res Cardiol. 2007;96(6):375-382. doi:10.1007/s00392-007-0513-0.

 

View original content:https://www.prnewswire.com/news-releases/abbott-receives-fda-clearance-and-ce-mark-for-next-generation-ultreon-3-0-ai-powered-coronary-imaging-platform-302755466.html

SOURCE Abbott

FAQ

What did Abbott (ABT) announce about Ultreon 3.0 on April 28, 2026?

Abbott announced FDA clearance and a CE Mark for Ultreon 3.0 on April 28, 2026. According to Abbott, the update integrates OCT imaging with AI-driven insights to support faster, more precise planning and stent placement during complex PCI procedures.

How does Ultreon 3.0's one-second OCT pullback affect PCI procedures for ABT?

The one-second OCT pullback captures high-resolution intravascular images quickly during PCI. According to Abbott, this enables faster image acquisition with lower or zero contrast, potentially benefiting patients with reduced kidney function.

What AI capabilities does Ultreon 3.0 provide for physicians using ABT systems?

Ultreon 3.0 offers AI-automated plaque assessment and stent-sizing guidance in real time. According to Abbott, the software helps identify plaque type, optimize stent location and size, and provide post-procedure assessment to verify improved blood flow.

Will Ultreon 3.0 reduce contrast use for patients during PCI with ABT devices?

Ultreon 3.0 supports low- or zero-contrast OCT imaging in many cases. According to Abbott, the platform's high-resolution imaging can reduce contrast exposure, which may help the roughly 25% of coronary artery disease patients with kidney disease.

How might Ultreon 3.0 affect treatment of complex PCI volumes for Abbott (ABT)?

Ultreon 3.0 targets complex PCI by combining imaging and AI to streamline decisions during procedures. According to Abbott, more than 600,000 U.S. and 885,000 European PCI procedures annually represent addressable procedural volume for the technology.